Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, rec...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Language: | en |
Published: |
MASSACHUSETTS MEDICAL SOC
2016
|
Online Access: | http://hdl.handle.net/10150/622478 http://arizona.openrepository.com/arizona/handle/10150/622478 |